Recent Advances in Nanomedicine for Modulating Intratumoral Bacteria in Cancer Therapy
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00677 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Yutao Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, PR China. Hauptthemen laut MEDLINE: Nanomedicine, Neoplasms, Bacteria. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 158 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer is a critical global public health issue, and conventional therapies (surgery, chemotherapy, and radiotherapy) are limited by adverse effects and tumor resistance. Emerging evidence underscores the role of intratumoral bacteria in exacerbating tumor progression, metastasis, and therapeutic resistance via the modulation of cancer cell dynamics and the tumor microenvironment. These bacteria also present translational potential as diagnostic, therapeutic, and prognostic targets. However, antibiotic-based strategies to reduce the bacterial burden often disrupt the commensal microbiota, induce resistance, and compromise therapeutic efficacy. Nanomedicines, characterized by enhanced biocompatibility, targeted delivery, and minimal systemic toxicity, have emerged as precision therapeutic modalities for intratumoral bacterial modulation. By eliminating pathogenic bacteria, reprogramming the immunosuppressive tumor microenvironment, and synergistically enhancing antitumor responses, nanoplatforms offer transformative potential in oncology. This review systematically summarizes recent advances in nanomedicine-based strategies for regulating intratumoral bacteria. On the basis of the composition of nanocarriers, nanomedicines are categorized into three major classes: polymeric nanoparticles, lipid-based and biorelated nanomaterials, and inorganic nanomaterials, and their potential clinical applications are discussed. By highlighting these advances, this review offers new perspectives and innovative strategies for improving cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shulan International Medical College, Zhejiang Shuren University, Hangzhou 310015, PR China.
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.
ORCID-Profile: Xiaoling Xu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Zhang, H., Xu, J., Xu, Z., Lou, J., Zheng, Q., Yuan, S., Zhu, L., & Xu, X. (2025). Recent Advances in Nanomedicine for Modulating Intratumoral Bacteria in Cancer Therapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00677
Vancouver
Zhang Y, Zhang H, Xu J, Xu Z, Lou J, Zheng Q, et al. Recent Advances in Nanomedicine for Modulating Intratumoral Bacteria in Cancer Therapy. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00677
BibTeX
@article{Zhang2025,
author = {Zhang, Yutao and Zhang, Hairui and Xu, Jiaxin and Xu, Zicong and Lou, Jingyang and Zheng, Qi and Yuan, Shuqi and Zhu, Luwen and Xu, Xiaoling},
title = {Recent Advances in Nanomedicine for Modulating Intratumoral Bacteria in Cancer Therapy},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00677}
}
EUVIMED